Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer
Authors
Keywords
-
Journal
Journal of Immunology Research
Volume 2018, Issue -, Pages 1-9
Publisher
Hindawi Limited
Online
2018-09-04
DOI
10.1155/2018/6248590
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma
- (2017) Maria C. Svensson et al. Oncotarget
- A Four-Factor Immunoscore System That Predicts Clinical Outcome for Stage II/III Gastric Cancer
- (2017) Ti Wen et al. Cancer Immunology Research
- Tumor-Associated Monocytes/Macrophages Impair NK-Cell Function via TGFβ1 in Human Gastric Cancer
- (2017) Liu-sheng Peng et al. Cancer Immunology Research
- TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
- (2016) Hung C. Tran et al. CLINICAL CANCER RESEARCH
- Altered phenotypic and functional characteristics of CD3+CD56+ NKT-like cells in human gastric cancer
- (2016) Liu-sheng Peng et al. Oncotarget
- Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15
- (2016) Yamila Sol Rocca et al. Frontiers in Immunology
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors
- (2015) Yutaka Fujiwara et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Age-related changes in natural killer cell repertoires: impact on NK cell function and immune surveillance
- (2015) Angela R. Manser et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
- (2015) Michael Lahn et al. Drug Design Development and Therapy
- Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy
- (2015) Cariad Chester et al. Frontiers in Immunology
- Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
- (2014) Jordi Rodón et al. INVESTIGATIONAL NEW DRUGS
- Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients
- (2014) Katarina M. Mirjačić Martinović et al. MELANOMA RESEARCH
- Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
- (2013) Eric O. Long et al. Annual Review of Immunology
- NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs
- (2013) V. Beziat et al. BLOOD
- The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
- (2013) Jérôme Galon et al. IMMUNITY
- Cutting Edge: Antibody-Dependent Memory-like NK Cells Distinguished by FcR Deficiency
- (2013) T. Zhang et al. JOURNAL OF IMMUNOLOGY
- Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer
- (2013) Yun-Peng Peng et al. Journal of Translational Medicine
- Phenotypic and Functional Characteristics of Blood Natural Killer Cells from Melanoma Patients at Different Clinical Stages
- (2013) Giulia Fregni et al. PLoS One
- Increased tumor-infiltrating CD8+Foxp3+ T lymphocytes are associated with tumor progression in human gastric cancer
- (2012) Liu-sheng Peng et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CD8+ T Cells That Produce Interleukin-17 Regulate Myeloid-Derived Suppressor Cells and Are Associated With Survival Time of Patients With Gastric Cancer
- (2012) Yuan Zhuang et al. GASTROENTEROLOGY
- Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions
- (2012) Yan Wu et al. HEPATOLOGY
- Identification of human NK cells that are deficient for signaling adaptor FcR and specialized for antibody-dependent immune functions
- (2012) I. Hwang et al. INTERNATIONAL IMMUNOLOGY
- IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
- (2011) D. M. Benson et al. BLOOD
- Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
- (2011) Emilie Mamessier et al. JOURNAL OF CLINICAL INVESTIGATION
- Innate or Adaptive Immunity? The Example of Natural Killer Cells
- (2011) E. Vivier et al. SCIENCE
- Human NK cells display major phenotypic and functional changes over the life span
- (2010) Magali Le Garff-Tavernier et al. AGING CELL
- Genotypes of NK Cell KIR Receptors, Their Ligands, and Fc Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy
- (2010) D. C. Delgado et al. CANCER RESEARCH
- TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression
- (2010) Li Yang et al. TRENDS IN IMMUNOLOGY
- TGFβ in Cancer
- (2008) Joan Massagué CELL
- Up on the tightrope: natural killer cell activation and inhibition
- (2008) Lewis L Lanier NATURE IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now